News

51. Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA 5/8/2012

    Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, recently announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

52. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 4/20/2012

    A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

53. Roche's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer 4/2/2012
    Roche recently announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1).
54. Many Cancer Rates Continue To Decline 4/2/2012
    Death rates from all cancers combined for men, women, and children continued to decrease in the United States between 2004 and 2008.
55. XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard Of Care For The Treatment And Secondary Prevention Of Venous Blood Clots In Patients With Symptomatic Pulmonary Embolism In Pivotal Phase 3 Study 3/27/2012
    Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
56. Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol Up To 81 Percent In Phase 1b Study 3/26/2012
    Amgen (NASDAQ: AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins.
57. Ampio Announces Positive Preliminary Update On The Optina™ Clinical Trial To Treat Diabetic Macular Edema And Decision To Conclude The Study Ahead Of Schedule 3/20/2012
    Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
58. Data In NEJM Shows Novartis Drug Signifor Is First Therapy To Provide Rapid, Durable Benefit For Cushing's Disease Patients In Phase III Study 3/9/2012
    A study published in The New England Journal of Medicine (NEJM) found that the investigational drug Signifor (SOM230, pasireotide), normalized cortisol levels and showed clinical benefit in patients with Cushing's disease.
59. FDA Requests Additional Data On Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, For Expanded Use In Infants And Toddlers 2/13/2012
    Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) on its application for the expanded use of Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) in infants and toddlers from 2 months of age.
60. NIST Announces Program To ID Human Cell Lines For Research 2/9/2012
    The National Institute of Standards and Technology (NIST) has announced that it is launching a project to collect and catalog DNA identification data for up to 1,500 human cell lines used in biological and medical research.